Viking Therapeutics, Inc.
http://www.vikingtherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Viking Therapeutics, Inc.
Viking Wins First Round In Legal Battle With Ascletis Over THRβ Agonist
The US International Trade Commission looks set to ban the importation of Ascletis's THRβ agonist into the US for use in clinical trials due to an initial legal determination on potential infringement of trade secrets related to Viking's same-class candidate VK2809.
Metsera Enters Race With Potential Monthly GLP-1 Injection For Obesity
Five months after its debut, the company plans to take its candidate, MET-097, into Phase IIb development.
Aligos’s MASH Data Look Competitive, But Path Forward Is Unclear
Aligos’s THRβ agonist yielded hepatic fat reduction equal to or better than its class, but the biotech prefers moving forward with a partner. Hepatitis B may be the firm’s higher priority.
Amgen Gets Into Position For MariTide Development
In an interview, CFO Peter Griffith pointed to a boost in capex to build out capacity for the obesity drug, which the company expects to move into Phase III development in the near term.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice